title: [Treatment of acromegaly: a critical analysis of the last ten years].
abstract: The ten previous years in terms of acromegaly treatment were essentially characterized by the experience accumulated with new formulations of somatostatin analogues or new drugs such GH-receptor antagonists recently available. Surgery remains the first-line treatment and its results did not change despite the generalization of endoscopy, which mainly seems to decrease local side-effects. The setting of radiotherapy was essentially modified by the increasing use of gamma-knife or stereotactic radiotherapy; however, their results are essentially the same as the classic fractionated, conventional radiotherapy and nobody knows if it will decrease the side-effects of this therapeutic modality. Nevertheless, thanks to a multistep therapeutic strategy, combining the different therapeutic modalities, it has become very rare for acromegaly not to be controlled in a patient.
authors.affiliation: Service d'endocrinologie et des maladies de la reproduction, faculté de médecine Paris-Sud, université Paris XI, hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France. philippe.chanson@bct.ap-hop-paris.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Chanson
authors.forename: Peter
authors.initials: P
authors.lastname: Kamenický
mesh_terms: D000172:Acromegaly / Q000628:therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004704:Endocrinology / Q000379:methods* / Q000639:trends; D005069:Evaluation Studies as Topic; D006801:Humans; D015201:Meta-Analysis as Topic; D019635:Neurosurgical Procedures / Q000706:statistics & numerical data; D011878:Radiotherapy / Q000379:methods / Q000706:statistics & numerical data; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D018491:Dopamine Agonists; D013004:Somatostatin